Drug Profile
JNJ 39758979
Alternative Names: JNJ-39758979Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antiasthmatics; Antipruritics; Antirheumatics; Pyrimidines; Pyrrolidines; Skin disorder therapies
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Atopic dermatitis; Rheumatoid arthritis
Most Recent Events
- 11 May 2012 Johnson & Johnson withdraws a phase II trial in Asthma prior to enrolment (NCT01493882)
- 13 Jan 2012 Johnson & Johnson suspends a phase II trial in Rheumatoid arthritis in US (NCT01480388)
- 01 Dec 2011 Johnson & Johnson completes a phase I for Rheumatoid arthritis (combination therapy) in Germany and USA (NCT01442545)